Pharming Group (NASDAQ:PHAR) Sees Unusually-High Trading Volume – What’s Next?

Shares of Pharming Group (NASDAQ:PHAR) saw unusually-strong trading volume on Monday . Approximately 5,632 shares changed hands during trading, a decline of 9% from the previous session’s volume of 6,179 shares.The stock last traded at $8.39 and had previously closed at $8.65.

Analysts Set New Price Targets

Several brokerages have issued reports on PHAR. Jefferies Financial Group began coverage on shares of Pharming Group in a research note on Monday, December 9th. They issued a “buy” rating and a $14.00 price objective for the company. Oppenheimer lifted their price objective on Pharming Group from $30.00 to $39.00 and gave the company an “outperform” rating in a report on Friday, March 14th. Finally, HC Wainwright reiterated a “buy” rating and issued a $37.00 price target on shares of Pharming Group in a report on Thursday, March 20th.

Pharming Group Stock Down 0.7 %

The company has a debt-to-equity ratio of 0.41, a current ratio of 3.53 and a quick ratio of 2.76. The firm has a market capitalization of $565.34 million, a price-to-earnings ratio of -31.96 and a beta of -0.10. The business has a fifty day moving average price of $8.74 and a two-hundred day moving average price of $8.69.

Pharming Group (NASDAQ:PHAR) last posted its earnings results on Thursday, March 13th. The company reported $0.05 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.02). The business had revenue of $92.70 million for the quarter, compared to analyst estimates of $76.67 million. Pharming Group had a negative net margin of 6.09% and a negative return on equity of 7.65%. On average, equities analysts expect that Pharming Group will post -0.2 earnings per share for the current year.

Hedge Funds Weigh In On Pharming Group

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC grew its position in Pharming Group (NASDAQ:PHAR) by 16.8% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 47,997 shares of the company’s stock after acquiring an additional 6,887 shares during the period. Silverberg Bernstein Capital Management LLC owned about 0.07% of Pharming Group worth $483,000 at the end of the most recent quarter. Institutional investors own 0.03% of the company’s stock.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.